200 related articles for article (PubMed ID: 35947641)
1. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
Macha SJ; Koneru B; Burrow TA; Zhu C; Savitski D; Rahman RL; Ronaghan CA; Nance J; McCoy K; Eslinger C; Reynolds CP
Cancer Res; 2022 Sep; 82(18):3345-3358. PubMed ID: 35947641
[TBL] [Abstract][Full Text] [Related]
2. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
[TBL] [Abstract][Full Text] [Related]
3. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
4. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM
J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of p53 and/or AKT as a new therapeutic approach specifically targeting ALT cancers.
Ge Y; Wu S; Zhang Z; Li X; Li F; Yan S; Liu H; Huang J; Zhao Y
Protein Cell; 2019 Nov; 10(11):808-824. PubMed ID: 31115790
[TBL] [Abstract][Full Text] [Related]
7. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
[TBL] [Abstract][Full Text] [Related]
8. Alternative lengthening of telomeres in cancer stem cells in vivo.
Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.
Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R
Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461
[TBL] [Abstract][Full Text] [Related]
10. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
11. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
[TBL] [Abstract][Full Text] [Related]
12. ALT: A Multi-Faceted Phenomenon.
Sommer A; Royle NJ
Genes (Basel); 2020 Jan; 11(2):. PubMed ID: 32012790
[TBL] [Abstract][Full Text] [Related]
13. Telomeres and telomerase in sarcomas.
Matsuo T; Shimose S; Kubo T; Fujimori J; Yasunaga Y; Ochi M
Anticancer Res; 2009 Oct; 29(10):3833-6. PubMed ID: 19846916
[TBL] [Abstract][Full Text] [Related]
14. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
15. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies.
Gocha AR; Nuovo G; Iwenofu OH; Groden J
Am J Pathol; 2013 Jan; 182(1):41-8. PubMed ID: 23260199
[TBL] [Abstract][Full Text] [Related]
16. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.
Henson JD; Reddel RR
FEBS Lett; 2010 Sep; 584(17):3800-11. PubMed ID: 20542034
[TBL] [Abstract][Full Text] [Related]
17. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.
Jeyapalan JN; Mendez-Bermudez A; Zaffaroni N; Dubrova YE; Royle NJ
Int J Cancer; 2008 Jun; 122(11):2414-21. PubMed ID: 18311780
[TBL] [Abstract][Full Text] [Related]
18. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
Flynn RL; Cox KE; Jeitany M; Wakimoto H; Bryll AR; Ganem NJ; Bersani F; Pineda JR; SuvĂ ML; Benes CH; Haber DA; Boussin FD; Zou L
Science; 2015 Jan; 347(6219):273-7. PubMed ID: 25593184
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.
Heaphy CM; Subhawong AP; Hong SM; Goggins MG; Montgomery EA; Gabrielson E; Netto GJ; Epstein JI; Lotan TL; Westra WH; Shih IeM; Iacobuzio-Donahue CA; Maitra A; Li QK; Eberhart CG; Taube JM; Rakheja D; Kurman RJ; Wu TC; Roden RB; Argani P; De Marzo AM; Terracciano L; Torbenson M; Meeker AK
Am J Pathol; 2011 Oct; 179(4):1608-15. PubMed ID: 21888887
[TBL] [Abstract][Full Text] [Related]
20. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
Zhao S; Wang F; Liu L
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]